NCT00334295 - Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Endometrial Carcinoma

Interventions

DRUG

Fulvestrant

A monthly intramuscular application of 250 mg Fulvestrant as a 1st line endocrine therapy in patients with recurrent or metastatic endometrial carcinoma.

Trial Locations (9)

Unknown

Research Site, Erlangen

Research Site, Göttingen

Research Site, Halle

Research Site, Jena

Research Site, Lübeck

Research Site, Mainz

Research Site, Münster

Research Site, Neunkirchen

Research Site, Rostock